Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06)

Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06)

Abstract Background Immune checkpoint inhibitor (ICI) or irinotecan-based chemotherapy is frequently used after failure of second-line paclitaxel plus ramucirumab treatment for patients with locally advanced unresectable or metastatic advanced gastric cancer (AGC). This study aimed to compare the ef...

Full description

Bibliographic Details
Main Authors: Sung Hee Lim, Keun-Wook Lee, Jae-Joon Kim, Hyeon-Su Im, In-Ho Kim, Hye Sook Han, Dong-Hoe Koo, Jang Ho Cho, Chi Hoon Maeng, Min-Young Lee, Hyo Jin Lee, Jwa Hoon Kim, Sang Gon Park, Joo Young Jung, Seong-Hoon Shin, Ki Hyang Kim, Hyeyeong Kim, So Yeon Oh, Minsu Kang, Minkyu Jung, Sun Young Rha
Format: Article
Language:English
Published: BMC 2024-02-01
Series:BMC Cancer
Subjects:
Gastric cancer
Third-line treatment
Irinotecan
Nivolumab
Pembrolizumab
Online Access:https://doi.org/10.1186/s12885-024-11972-w

Internet

https://doi.org/10.1186/s12885-024-11972-w

Similar Items